ABSTRACT Background Chronic kidney disease is a growing public health problem worldwide, and the number of patients requiring renal replacement therapy is steadily increasing. Türkiye has experienced a similar rise in both the incidence and prevalence of renal replacement therapy over the past decades; however, national‐level projections of future renal replacement therapy demand are lacking. Aims This study aimed to forecast the future burden of renal replacement therapy in Türkiye by modeling historical incidence and prevalence trends using national registry data and demographic projections. Methods National renal replacement therapy registry data from 2012 to 2024 were analyzed together with demographic projections from the Turkish Statistical Institute extending to 2035. Four models were constructed separately for incidence and prevalence. Model performance was compared using the coefficient of determination, root mean square error, and Akaike information criterion. Leave‐one‐out cross‐validation was used to assess model robustness. The modeling was further validated on data from Japan and the United Kingdom. Results All models indicated a consistent upward trend in renal replacement therapy incidence in Türkiye over the next decade. By 2035, the prevalence of renal replacement therapy in Türkiye is projected to reach approximately 1150–1250 per million population. The models demonstrated strong goodness of fit, and cross‐validation supported good internal consistency, although the machine‐learning model showed some overfitting for prevalence. Conclusion The national demand for renal replacement therapy in Türkiye is projected to continue increasing through 2035. Incorporating predictive modeling into national registry surveillance can help guide proactive capacity planning and fair resource distribution for dialysis and transplantation services. At the same time, public health strategies aimed at preventing and slowing the progression of chronic kidney disease remain essential to mitigate the growing burden of end‐stage renal disease.
Akgül et al. (Thu,) studied this question.